North America Cell And Gene Therapy Cdmo Market Size & Outlook
North America cell and gene therapy cdmo market, 2018-2030 (US$M)
Related Markets
North America cell and gene therapy cdmo market highlights
- The North America cell and gene therapy cdmo market generated a revenue of USD 2,032.5 million in 2023.
- The market is expected to grow at a CAGR of 27.5% from 2024 to 2030.
- In terms of segment, pre-clinical was the largest revenue generating by phase in 2023.
- Pre-clinical is the most lucrative by phase segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 2,032.5 million |
| Market revenue in 2030 | USD 11,117.2 million |
| Growth rate | 27.5% (CAGR from 2023 to 2030) |
| Largest segment | Pre-clinical |
| Fastest growing segment | Pre-clinical |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre-clinical, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
Other key industry trends
- In terms of revenue, North America region accounted for 40.8% of the global cell and gene therapy cdmo market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 10,925.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy CDMO Market Scope
Cell And Gene Therapy CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America cell and gene therapy cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.22% in 2023. Horizon Databook has segmented the North America cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
North America accounts for 40.76% share in the global cell & gene therapy CDMO market due to growing investments in R&D of new drugs by pharmaceutical companies. The growth of the pharmaceutical industry in the U.S. and Canada is one of the key factors contributing to market growth.
In addition, the presence of key players and ongoing clinical trials are anticipated to drive market growth. Moreover, stringent regulatory requirements, particularly in the U.S. & Canada, necessitate specialized knowledge & compliance expertise, making CDMOs an attractive option for navigating regulatory hurdles.
Furthermore, increasing mergers & acquisitions among CDMOs to expand service offerings, geographic presence, and capabilities is expected to drive the North America cell & gene therapy CDMO market. For instance, in May 2023, uBriGene Biosciences acquired Mustang Bio’s, a cell & gene therapy manufacturing facility in Worcester, Massachusetts, for USD 11 million.
Reasons to subscribe to North America cell and gene therapy cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America cell and gene therapy cdmo market databook
-
Our clientele includes a mix of cell and gene therapy cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America cell and gene therapy cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into North America cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America cell and gene therapy cdmo market size, by country, 2018-2030 (US$M)
North America Cell And Gene Therapy CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
